Keeler Thomas Management LLC Boosts Stake in Repligen Co. (NASDAQ:RGEN)

Keeler Thomas Management LLC lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 68.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,979 shares of the biotechnology company’s stock after purchasing an additional 3,662 shares during the quarter. Keeler Thomas Management LLC’s holdings in Repligen were worth $1,294,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Blue Trust Inc. lifted its position in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the last quarter. Resources Management Corp CT ADV acquired a new stake in shares of Repligen during the third quarter valued at about $37,000. Quarry LP raised its stake in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the period. UMB Bank n.a. lifted its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 129 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RGEN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Friday. Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Stock Performance

Shares of RGEN opened at $164.74 on Tuesday. The stock has a 50-day simple moving average of $155.30 and a 200-day simple moving average of $148.57. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $203.13. The stock has a market capitalization of $9.23 billion, a PE ratio of -323.02, a PEG ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. On average, analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.